APM
PHAT icon

Avidity Partners Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Avidity Partners Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.56M Buy
498,780
+292,704
+142% +$3.7M 0.59% 21
2025
Q4 		$3.42M Sell
206,076
-99,924
-33% -$1.43M 0.99% 21
2025
Q3 		$3.6M Sell
306,000
-758,500
-71% -$7.83M 0.82% 30
2025
Q2 		$10.2M Buy
1,064,500
+264,500
+33% +$1.46M 2.03% 16
2025
Q1 		$5.02M Sell
800,000
-590,100
-42% -$3.58M 0.96% 38
2024
Q4 		$11.3M Sell
1,390,100
-414,393
-23% -$5.13M 1.11% 37
2024
Q3 		$32.6M Buy
1,804,493
+184,493
+11% +$2.58M 1.66% 24
2024
Q2 		$16.7M Sell
1,620,000
-115,000
-7% -$1.18M 0.71% 51
2024
Q1 		$18.4M Buy
1,735,000
+13,420
+0.8% +$114K 0.59% 53
2023
Q4 		$15.7M Buy
1,721,580
+104,280
+6% +$898K 0.57% 51
2023
Q3 		$16.8M Sell
1,617,300
-332,400
-17% -$4.56M 0.68% 55
2023
Q2 		$27.9M Sell
1,949,700
-98,900
-5% -$1.14M 0.98% 42
2023
Q1 		$14.6M Buy
2,048,600
+148,600
+8% +$1.31M 0.49% 61
2022
Q4 		$21.3M Sell
1,900,000
-6,800
-0.4% -$70.1K 0.46% 50
2022
Q3 		$21.1M Sell
1,906,800
-13,000
-0.7% -$124K 0.43% 52
2022
Q2 		$16.2M Sell
1,919,800
-26,200
-1% -$269K 0.37% 41
2022
Q1 		$26.5M Buy
1,946,000
+50,000
+3% +$808K 0.55% 46
2021
Q4 		$37.3M Buy
+1,896,000
New +$44.6M 0.79% 42
2021
Q1 		– Sell
-152,500
Closed -$5.07M – 118
2020
Q4 		$5.07M Buy
+152,500
New +$6.18M 0.16% 81

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Avidity Partners Management's PHAT Position: Q1 2026 in Review

Avidity Partners Management increased its Phathom Pharmaceuticals (PHAT) stake by 142% in Q1 2026, buying an estimated $3.7M and bringing the position to 498,780 shares worth $5.56M. The position accounts for 0.59% of the portfolio, ranked #21.

Avidity Partners Management first reported a position in PHAT in Q4 2020 and has held it in 19 quarters since. The position peaked at $37.3M in Q4 2021. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Avidity Partners Management held 498,780 shares of Phathom Pharmaceuticals worth $5.56M as of Q1 2026.
  • Avidity Partners Management bought 292,704 Phathom Pharmaceuticals shares in Q1 2026, an estimated $3.7M.
  • Phathom Pharmaceuticals made up 0.59% of Avidity Partners Management's portfolio in Q1 2026, its #21 holding.
  • Avidity Partners Management first reported a position in Phathom Pharmaceuticals in Q4 2020 and has held it in 19 quarters since.
  • Avidity Partners Management's Phathom Pharmaceuticals position peaked at $37.3M in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.